DK2906947T3 - Multiplanart lateralflowassay med omdirigeringszone - Google Patents
Multiplanart lateralflowassay med omdirigeringszone Download PDFInfo
- Publication number
- DK2906947T3 DK2906947T3 DK14760824.4T DK14760824T DK2906947T3 DK 2906947 T3 DK2906947 T3 DK 2906947T3 DK 14760824 T DK14760824 T DK 14760824T DK 2906947 T3 DK2906947 T3 DK 2906947T3
- Authority
- DK
- Denmark
- Prior art keywords
- sample
- zone
- binding partner
- test
- analyte
- Prior art date
Links
- 238000003556 assay Methods 0.000 title claims description 50
- 238000012360 testing method Methods 0.000 claims description 694
- 238000009739 binding Methods 0.000 claims description 673
- 230000027455 binding Effects 0.000 claims description 670
- 239000012491 analyte Substances 0.000 claims description 327
- 238000001514 detection method Methods 0.000 claims description 135
- 230000004888 barrier function Effects 0.000 claims description 111
- 238000011144 upstream manufacturing Methods 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 47
- 239000000758 substrate Substances 0.000 claims description 36
- 239000000126 substance Substances 0.000 claims description 13
- 230000001934 delay Effects 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 1203
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 90
- 102000004190 Enzymes Human genes 0.000 description 79
- 108090000790 Enzymes Proteins 0.000 description 79
- 229940088598 enzyme Drugs 0.000 description 79
- 239000000463 material Substances 0.000 description 69
- 238000004458 analytical method Methods 0.000 description 67
- 239000003153 chemical reaction reagent Substances 0.000 description 63
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 54
- 229910052709 silver Inorganic materials 0.000 description 54
- 239000004332 silver Substances 0.000 description 54
- 102100032752 C-reactive protein Human genes 0.000 description 52
- 241000283973 Oryctolagus cuniculus Species 0.000 description 52
- 239000011324 bead Substances 0.000 description 50
- 239000012146 running buffer Substances 0.000 description 49
- 239000000427 antigen Substances 0.000 description 46
- 108091007433 antigens Proteins 0.000 description 46
- 102000036639 antigens Human genes 0.000 description 46
- 229960002685 biotin Drugs 0.000 description 45
- 235000020958 biotin Nutrition 0.000 description 45
- 239000011616 biotin Substances 0.000 description 45
- 230000009089 cytolysis Effects 0.000 description 45
- 239000000872 buffer Substances 0.000 description 44
- 238000012546 transfer Methods 0.000 description 44
- 125000003147 glycosyl group Chemical group 0.000 description 43
- 239000003795 chemical substances by application Substances 0.000 description 42
- 239000004816 latex Substances 0.000 description 38
- 229920000126 latex Polymers 0.000 description 38
- 239000012528 membrane Substances 0.000 description 38
- 241000700584 Simplexvirus Species 0.000 description 37
- 239000002250 absorbent Substances 0.000 description 35
- 230000002745 absorbent Effects 0.000 description 35
- 239000000123 paper Substances 0.000 description 35
- 108010087904 neutravidin Proteins 0.000 description 34
- 108090001090 Lectins Proteins 0.000 description 33
- 102000004856 Lectins Human genes 0.000 description 33
- 239000002523 lectin Substances 0.000 description 33
- 108090001008 Avidin Proteins 0.000 description 32
- 239000012530 fluid Substances 0.000 description 32
- 238000007906 compression Methods 0.000 description 31
- 230000006835 compression Effects 0.000 description 31
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 30
- 150000007523 nucleic acids Chemical class 0.000 description 30
- 108020003175 receptors Proteins 0.000 description 30
- 102000005962 receptors Human genes 0.000 description 30
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 29
- 238000005538 encapsulation Methods 0.000 description 29
- 239000007788 liquid Substances 0.000 description 29
- 210000004379 membrane Anatomy 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 238000000159 protein binding assay Methods 0.000 description 28
- 238000010828 elution Methods 0.000 description 25
- 239000002105 nanoparticle Substances 0.000 description 25
- 108010090804 Streptavidin Proteins 0.000 description 24
- 230000003321 amplification Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 21
- 230000009870 specific binding Effects 0.000 description 21
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 20
- 239000002699 waste material Substances 0.000 description 20
- 239000000835 fiber Substances 0.000 description 19
- 150000003378 silver Chemical class 0.000 description 18
- 241000894007 species Species 0.000 description 17
- 239000000020 Nitrocellulose Substances 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- 229920001220 nitrocellulos Polymers 0.000 description 16
- -1 but not limited to Chemical class 0.000 description 15
- 238000003018 immunoassay Methods 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 230000002452 interceptive effect Effects 0.000 description 13
- 208000035143 Bacterial infection Diseases 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 12
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 12
- 208000022362 bacterial infectious disease Diseases 0.000 description 12
- 108090000623 proteins and genes Chemical class 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 108091023037 Aptamer Proteins 0.000 description 11
- 208000036142 Viral infection Diseases 0.000 description 11
- 238000012125 lateral flow test Methods 0.000 description 11
- 229920002521 macromolecule Polymers 0.000 description 11
- 244000052769 pathogen Species 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000001525 receptor binding assay Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 240000004713 Pisum sativum Species 0.000 description 10
- 235000016816 Pisum sativum subsp sativum Nutrition 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 10
- 230000009977 dual effect Effects 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 108091000699 pea lectin Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000010839 body fluid Substances 0.000 description 9
- 229920001778 nylon Polymers 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 230000003622 anti-hsv Effects 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 description 8
- 239000005020 polyethylene terephthalate Substances 0.000 description 8
- 239000000700 radioactive tracer Substances 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 238000012123 point-of-care testing Methods 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 230000002902 bimodal effect Effects 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 5
- 238000012875 competitive assay Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229920004934 Dacron® Polymers 0.000 description 4
- 108090000288 Glycoproteins Chemical class 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000001045 blue dye Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000012468 concentrated sample Substances 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001429 visible spectrum Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000004579 marble Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000001044 red dye Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 238000013096 assay test Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- RNKLPBMXHDOSEU-UHFFFAOYSA-N CC1(CCCCCCC1)N Chemical compound CC1(CCCCCCC1)N RNKLPBMXHDOSEU-UHFFFAOYSA-N 0.000 description 1
- CXOZQHPXKPDQGT-UHFFFAOYSA-N CC1C=CCC1 Chemical compound CC1C=CCC1 CXOZQHPXKPDQGT-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012696 Interfacial polycondensation Methods 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- WQJUXXKWIKZLQF-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)-(methoxymethyl)amino]methanol Chemical compound COCN(CO)C1=NC(N)=NC(N)=N1 WQJUXXKWIKZLQF-UHFFFAOYSA-N 0.000 description 1
- MBHRHUJRKGNOKX-UHFFFAOYSA-N [(4,6-diamino-1,3,5-triazin-2-yl)amino]methanol Chemical compound NC1=NC(N)=NC(NCO)=N1 MBHRHUJRKGNOKX-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002800 charge carrier Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 230000003098 cholesteric effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000002158 endotoxin Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000001559 fluids and secretion Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011086 glassine Substances 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 102000048122 human MX1 Human genes 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 229920006008 lipopolysaccharide Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
- G01N33/54389—Immunochromatographic test strips based on lateral flow with bidirectional or multidirectional lateral flow, e.g. wherein the sample flows from a single, common sample application point into multiple strips, lanes or zones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structures Of Non-Positive Displacement Pumps (AREA)
Claims (15)
1. Lateralflowindretning til påvisning af en analyt i en prøve omfattende: en prøvekompressor; en teststrimmel omfattende en testzone og en omdirigeringszone opstrøms for testzonen, hvor omdirigeringszonen afbryder et lateralt flow på teststrim-len; et konjugat omfattende en første bindingspartner til analytten og en label; og en anden bindingspartner til analytten; og en prøvepåføringszone, hvor en prøve påføres på lateralflowindretningen, hvor prøvepåføringszonen er placeret på et sted udvalgt fra gruppen bestående af: i) på teststrimlen opstrøms for påvisningszonen; ii) på prøvekom-pressoren; og iii) på en prøveopsamler omfattende en prøveopsamlingsdel til opsamling af prøven; hvor en bestanddel udvalgt fra gruppen bestående af konjugatet, den anden bindingspartner og både konjugatet og den anden bindingspartner ikke er placeret på teststrimlen, inden lateralflowindretningen anvendes; og hvor prøvekompressoren danner en bro over omdirigeringszonen for at omdirigere et flow hen mod prøvekompressoren og føre flowet tilbage til teststrimlen for enden af omdirigeringszonen.
2. Lateralflowindretning ifølge krav 1, hvor prøveopsamleren, når prøvepåføringszonen er placeret på en prøveopsamler, er placeret mellem prøvekompressoren og teststrimlen i en vertikal stak.
3. Lateralflowindretning ifølge krav 1, hvor omdirigeringszonen omfatter: (A) en fysisk barriere, som stopper eller forsinker et flow i en lateral retning på teststrimlen, (B) en kemisk barriere, som stopper eller forsinker et flow i en lateral retning på teststrimlen, eller (C) en spalte, som stopper et flow i en lateral retning på teststrimlen.
4. Lateralflowindretning ifølge krav 1, hvor omdirigeringszonen omfatter en fysisk barriere, som stopper eller forsinker et flow i en lateral retning på teststrimlen, og hvor den fysiske barriere omfatter indkapslede komponenter, og den fysiske barriere opløser sig, når et elueringsmiddel er påført.
5. Lateralflowindretning ifølge krav 1, hvor prøvekompressoren omfatter et underlag, og hvor konjugatet eller den anden bindingspartner er placeret på underlaget, inden lateralflowindretningen anvendes.
6. Lateralflowindretning ifølge krav 1, hvor prøvekompressoren omfatter et underlag omfattende en første kontrolbindingspartner placeret på underlaget, og en anden bindingspartner er immobiliseret i en kontrolzone af teststrimlen, hvor den første kontrolbindingspartner er en bindingspartner for den anden kontrolbindingspartner.
7. Lateralflowindretning ifølge krav 1, hvor lateralflowindretningen er udformet således, at et positivt resultat kun opnås, når analytten er indfanget i testzo-nen ved dannelse af et kompleks mellem analytten, den første bindingspartner og den anden bindingspartner.
8. Lateralflowindretning ifølge krav 1, hvor testzonen ikke omfatter noget mo-lekyle, som specifikt binder analytten.
9. Lateralflowindretning ifølge krav 1, hvor den anden bindingspartner omfatter et mærke, og testzonen omfatter en immobiliseret bindingspartner af mærket.
10. Fremgangsmåde til at køre et assay på en prøve på en lateralflowindretning omfattende en teststrimmel og en prøvekompressor, hvor fremgangs-måden omfatter de følgende trin: a) at placere en prøve på lateralflowindretningen; b) at afbryde et lateralt flow på teststrimlen ved at inddrage en omdirigerings-zone på teststrimlen; c) at omdirigere det afbrudte flow til prøvekompressoren ved at påføre et tryk på indretningen under anvendelse af prøvekompressoren; og d) at føre flowet tilbage til teststrimlen for enden af omdirigeringszonen.
11. Fremgangsmåde ifølge krav 10, hvor, prøven i trin a) placeres på en prø-vepåføringszone placeret på et sted udvalgt fra gruppen bestående af: i) på teststrimlen opstrøms for en påvisningszone; ii) på prøvekompressoren; og iii) på en prøveopsamler omfattende en prøveopsamlingsdel til opsamling af prøven.
12. Fremgangsmåde ifølge krav 11, hvor, når prøven er placeret på en prøveopsamler, prøveopsamleren er placeret mellem prøvekompressoren og teststrimlen i en vertikal stak; og eventuelt hvor trin a) yderligere omfatter at placere et underlag med en bin-dingspartner til en analyt på den vertikale stak, og hvor i trin d) mindst en del af bindingspartneren overføres til teststrimlen.
13. Fremgangsmåde ifølge krav 10, hvor omdirigeringszonen omfatter en fysisk barriere, som stopper eller forsinker et flow i en lateral retning på teststrimlen; og eventuelt hvor den fysiske barriere omfatter mindst en indkapslet komponent, yderligere omfattede trinnet med, at den fysiske barriere opløser sig for at frigive den indkapslede komponent.
14. Fremgangsmåde ifølge krav 10, hvor omdirigeringszonen omfatter en spalte, som stopper et flow i en lateral retning på teststrimlen.
15. Fremgangsmåde ifølge krav 10, hvor prøvekompressoren omfatter en komponent udvalgt fra gruppen bestående af af en første bindingspartner, en anden bindingspartner og både den første bindingspartner og den anden bindingspartner.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/788,616 US8815609B2 (en) | 2008-05-20 | 2013-03-07 | Multiplanar lateral flow assay with diverting zone |
| US13/790,125 US20130196310A1 (en) | 2008-05-20 | 2013-03-08 | Method and Device for Combined Detection of Viral and Bacterial Infections |
| US13/790,160 US8962260B2 (en) | 2008-05-20 | 2013-03-08 | Method and device for combined detection of viral and bacterial infections |
| PCT/US2014/019773 WO2014137860A2 (en) | 2013-03-07 | 2014-03-03 | Multiplanar lateral flow assay with diverting zone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2906947T3 true DK2906947T3 (da) | 2017-03-06 |
Family
ID=51491815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14760824.4T DK2906947T3 (da) | 2013-03-07 | 2014-03-03 | Multiplanart lateralflowassay med omdirigeringszone |
| DK14760721.2T DK2909331T3 (da) | 2013-03-07 | 2014-03-03 | Fremgangsmåde og indretning til kombineret detektering af virus- og bakterieinfektioner |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14760721.2T DK2909331T3 (da) | 2013-03-07 | 2014-03-03 | Fremgangsmåde og indretning til kombineret detektering af virus- og bakterieinfektioner |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP2909331B1 (da) |
| JP (5) | JP6521525B2 (da) |
| KR (4) | KR102489679B1 (da) |
| AU (3) | AU2014226175A1 (da) |
| BR (2) | BR112015021199B1 (da) |
| CA (2) | CA2897494A1 (da) |
| DK (2) | DK2906947T3 (da) |
| ES (2) | ES2743128T3 (da) |
| HK (1) | HK1213985A1 (da) |
| WO (2) | WO2014137860A2 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130196310A1 (en) | 2008-05-20 | 2013-08-01 | Rapid Pathogen Screening, Inc. | Method and Device for Combined Detection of Viral and Bacterial Infections |
| GB2528657B (en) * | 2014-07-24 | 2019-03-13 | Intelligent Fingerprinting Ltd | Sample analysing device |
| KR20160140186A (ko) * | 2015-05-29 | 2016-12-07 | 삼성전자주식회사 | 분석용 스트립, 분석용 스트립을 이용한 장치 및 시스템 |
| JP6595818B2 (ja) * | 2015-06-30 | 2019-10-23 | 田中貴金属工業株式会社 | 免疫クロマト分析装置及び免疫クロマト分析方法 |
| DE102015218442A1 (de) * | 2015-09-25 | 2017-03-30 | Robert Bosch Gmbh | Biosensor und Verfahren zum Nachweis von Keimen |
| US10808287B2 (en) * | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
| KR20170099738A (ko) * | 2016-02-23 | 2017-09-01 | 노을 주식회사 | 접촉식 염색 패치 및 그 제조 방법 |
| PL3287785T3 (pl) * | 2016-08-24 | 2019-05-31 | Protzek Ges Fuer Biomedizinische Technik Gmbh | Urządzenie do wizualnego wykrywania analitów w ciekłej próbce |
| KR101948408B1 (ko) * | 2016-11-18 | 2019-02-14 | 주식회사 켈스 | 측방 유동 분석 스트립용 농축 키트 |
| WO2018093175A1 (ko) * | 2016-11-18 | 2018-05-24 | 주식회사 켈스 | 측방 유동 분석 스트립용 농축 키트 |
| KR20240059633A (ko) * | 2017-06-28 | 2024-05-07 | 벡톤 디킨슨 앤드 컴퍼니 | 고농도의 분석물을 포함한 분석물을 측정하기 위한 용량 반응 곡선의 신호 부분을 감소시키는 단계를 사용하는 샌드위치-유형 분석법 |
| HUE054089T2 (hu) * | 2017-11-22 | 2021-08-30 | Dewact Labs GmbH | Eljárás és készülék megkülönböztetésre vírusos és bakteriális fertõzések között |
| KR102147368B1 (ko) * | 2018-03-30 | 2020-08-24 | (주)타스컴 | 면역 크로마토그래피 센서 카트리지 |
| KR102147374B1 (ko) * | 2018-03-30 | 2020-08-24 | (주)타스컴 | 면역 크로마토그래피 측정 장치 및 방법 |
| US10928394B2 (en) * | 2019-02-07 | 2021-02-23 | Julian R. K. Kage | Rapid test for lyme bacteria |
| KR20220075271A (ko) * | 2019-05-27 | 2022-06-08 | 엘룸 리미티드 | 경쟁적 검정 대조군을 갖는 측면 흐름 시험 스트립 |
| CN210626494U (zh) * | 2019-07-23 | 2020-05-26 | 英科新创(厦门)科技股份有限公司 | 一种血型抗原检测组件 |
| WO2021205433A1 (en) * | 2020-04-05 | 2021-10-14 | Rapid Bio Pass Ltd. | Lateral flow test utensils |
| JP7846017B2 (ja) | 2020-04-09 | 2026-04-14 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 気道感染症の診断のためのバイオマーカー |
| WO2021211595A1 (en) * | 2020-04-13 | 2021-10-21 | Mbio Diagnostics, Inc. | Simultaneous detection of humoral and inflammatory biomarkers |
| EP3904879A1 (en) * | 2020-04-27 | 2021-11-03 | Abacuslabs Ltd. | A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions |
| CN113466461B (zh) * | 2021-08-20 | 2022-03-18 | 广东省第二人民医院（广东省卫生应急医院） | 一种磷脂酶a2侧向层析检测试纸条、检测卡及其应用 |
| GB202216036D0 (en) * | 2022-10-30 | 2022-12-14 | Wilson Alistair Richard Ian | A diagnostic device for the early identification of microbial infection types, in biological samples |
| AU2023388188A1 (en) * | 2022-12-08 | 2025-06-19 | Diag-Nose Medical Pty Ltd | Methods for diagnosing and treating viral and bacterial sinonasal infection |
| KR102911804B1 (ko) * | 2024-02-01 | 2026-01-13 | 광주과학기술원 | 다중 진단 멤브레인 센서 |
| GB202406490D0 (en) * | 2024-05-09 | 2024-06-26 | Septest Ltd | Diagnostic device |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648274A (en) * | 1991-05-29 | 1997-07-15 | Smithkline Diagnostics, Inc. | Competitive immunoassay device |
| FI92882C (fi) * | 1992-12-29 | 1995-01-10 | Medix Biochemica Ab Oy | Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi |
| US5415994A (en) * | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
| DE4439429C2 (de) | 1994-07-25 | 1997-11-20 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis der Kontamination einer Oberfläche mit einem Analyten |
| US6077665A (en) * | 1996-05-07 | 2000-06-20 | The Board Of Trustees Of The Leland Stanford Junior University | Rapid assay for infection in neonates |
| DE19622503C2 (de) | 1996-06-05 | 1998-07-09 | Securetec Sicherheitstechnolog | Verfahren zum Nachweis von Analyten auf einer Oberfläche |
| US6297020B1 (en) * | 1999-03-01 | 2001-10-02 | Bayer Corporation | Device for carrying out lateral-flow assays involving more than one analyte |
| DE10054093B4 (de) * | 2000-11-01 | 2006-02-09 | peS Gesellschaft für medizinische Diagnose-Systeme mbH | Verfahren zur Bestimmung der Antigenkonzentration in einer Probe mittels Fluoreszenzimmuntests |
| EP1221449A1 (en) * | 2000-12-22 | 2002-07-10 | Dsm N.V. | Peroxide compositions with reactive diluents |
| US6818452B2 (en) * | 2001-04-23 | 2004-11-16 | Branan Medical Corp. | Lateral flow contact test apparatus |
| AU2003221157A1 (en) * | 2002-03-22 | 2003-10-08 | Kyowa Medex Co., Ltd. | Method of judging viral infection |
| JP4233382B2 (ja) * | 2002-05-22 | 2009-03-04 | シスメックス株式会社 | 免疫測定方法、免疫測定装置、及び免疫測定用試薬 |
| JP2007524816A (ja) * | 2003-06-20 | 2007-08-30 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 細い均一な試薬ストリップの製造方法およびその試薬 |
| EP1718973B1 (en) * | 2004-02-09 | 2009-09-09 | Rapid Pathogen Screening Inc. | Method for the rapid diagnosis of targets in human body fluids |
| US7488298B2 (en) * | 2004-10-08 | 2009-02-10 | Roche Diagnostics Operations, Inc. | Integrated lancing test strip with capillary transfer sheet |
| JP2006199798A (ja) * | 2005-01-19 | 2006-08-03 | Mitsubishi Rayon Co Ltd | 反応性官能基を有する微粒子 |
| EP1686378B1 (en) * | 2005-01-28 | 2010-11-17 | DNT Scientific Research, LLC | Fluid flow diffuser for immunological testing devices and method |
| US8614101B2 (en) * | 2008-05-20 | 2013-12-24 | Rapid Pathogen Screening, Inc. | In situ lysis of cells in lateral flow immunoassays |
| US20070059682A1 (en) | 2005-09-13 | 2007-03-15 | Rapid Pathogen Screening Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
| WO2006098804A2 (en) * | 2005-03-11 | 2006-09-21 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| US7803319B2 (en) * | 2005-04-29 | 2010-09-28 | Kimberly-Clark Worldwide, Inc. | Metering technique for lateral flow assay devices |
| US8153444B2 (en) * | 2005-10-13 | 2012-04-10 | Auric Enterprises, Llc | Immuno gold lateral flow assay |
| US7279136B2 (en) | 2005-12-13 | 2007-10-09 | Takeuchi James M | Metering technique for lateral flow assay devices |
| US9239329B2 (en) * | 2006-12-18 | 2016-01-19 | Japan Science And Technology Agency | Method of measuring interaction between biomaterial and sugar chain, method of evaluating biomaterial in sugar chain selectivity, method of screening biomaterial, method of patterning biomaterials, and kits for performing these methods |
| WO2009108224A1 (en) * | 2007-11-16 | 2009-09-03 | Eugene Tu | Viral detection apparatus and method |
| US8962260B2 (en) * | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
| US9910036B2 (en) * | 2008-05-20 | 2018-03-06 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
| US8609433B2 (en) * | 2009-12-04 | 2013-12-17 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
| US8815609B2 (en) * | 2008-05-20 | 2014-08-26 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with diverting zone |
| WO2009152209A2 (en) * | 2008-06-10 | 2009-12-17 | Rapid Pathogen Screening, Inc. | Combined visual/fluorescence analyte detection test |
| EP2313527A4 (en) * | 2008-07-15 | 2012-11-21 | Rapid Pathogen Screening Inc | Lateral flow NUCLEIC DETECTOR |
| CA2741114A1 (en) * | 2008-10-24 | 2010-04-29 | Cornelis Lammert Verweij | Biomarkers for predicting the development of chronic autoimmune diseases |
| US20100173423A1 (en) * | 2009-01-06 | 2010-07-08 | Inverness Medical Switzerland Gmbh | Multiple testing apparatus and method |
| AU2010325893B2 (en) * | 2009-12-04 | 2014-05-29 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
| US9709565B2 (en) * | 2010-04-21 | 2017-07-18 | Memed Diagnostics Ltd. | Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof |
-
2014
- 2014-03-03 DK DK14760824.4T patent/DK2906947T3/da active
- 2014-03-03 KR KR1020217035374A patent/KR102489679B1/ko active Active
- 2014-03-03 ES ES14760721T patent/ES2743128T3/es active Active
- 2014-03-03 JP JP2015561486A patent/JP6521525B2/ja active Active
- 2014-03-03 ES ES14760824.4T patent/ES2620384T3/es active Active
- 2014-03-03 CA CA2897494A patent/CA2897494A1/en active Pending
- 2014-03-03 KR KR1020157027376A patent/KR102209489B1/ko active Active
- 2014-03-03 HK HK16101859.0A patent/HK1213985A1/zh unknown
- 2014-03-03 EP EP14760721.2A patent/EP2909331B1/en active Active
- 2014-03-03 JP JP2015561488A patent/JP6293797B2/ja not_active Expired - Fee Related
- 2014-03-03 EP EP19175740.0A patent/EP3591397A1/en not_active Ceased
- 2014-03-03 AU AU2014226175A patent/AU2014226175A1/en not_active Abandoned
- 2014-03-03 DK DK14760721.2T patent/DK2909331T3/da active
- 2014-03-03 BR BR112015021199-2A patent/BR112015021199B1/pt active IP Right Grant
- 2014-03-03 WO PCT/US2014/019773 patent/WO2014137860A2/en not_active Ceased
- 2014-03-03 WO PCT/US2014/019771 patent/WO2014137858A1/en not_active Ceased
- 2014-03-03 BR BR112015021317A patent/BR112015021317A2/pt not_active Application Discontinuation
- 2014-03-03 AU AU2014226173A patent/AU2014226173B2/en active Active
- 2014-03-03 EP EP14760824.4A patent/EP2906947B1/en active Active
- 2014-03-03 KR KR1020217002397A patent/KR102322094B1/ko active Active
- 2014-03-03 CA CA2897495A patent/CA2897495C/en active Active
- 2014-03-03 KR KR1020157027223A patent/KR102130186B1/ko not_active Expired - Fee Related
-
2019
- 2019-04-20 JP JP2019080579A patent/JP6892890B2/ja active Active
-
2020
- 2020-09-17 AU AU2020233741A patent/AU2020233741B2/en active Active
-
2021
- 2021-01-27 JP JP2021011320A patent/JP2021081437A/ja active Pending
-
2022
- 2022-07-04 JP JP2022107859A patent/JP2022136109A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2906947T3 (da) | Multiplanart lateralflowassay med omdirigeringszone | |
| US8815609B2 (en) | Multiplanar lateral flow assay with diverting zone | |
| US8609433B2 (en) | Multiplanar lateral flow assay with sample compressor | |
| EP2507632B1 (en) | Multiplanar lateral flow assay with sample compressor | |
| US9068981B2 (en) | Lateral flow assays with time delayed components | |
| US8445293B2 (en) | Method to increase specificity and/or accuracy of lateral flow immunoassays | |
| US7780915B2 (en) | Fecal sample test device and methods of use | |
| KR101157042B1 (ko) | 개선된 측면 이동 면역분석법과 이를 위한 디바이스 | |
| EP2313775A2 (en) | In situ lysis of cells in lateral flow immunoassays |